AndreaBozzo/ceres-open-data-index huggingface dataset:
PLACES: Local Data for Better Health, Place Data 2021 release

This dataset contains model-based place (incorporated and census designated places) level estimates for the PLACES 2021 release. PLACES is the expansion of the original 500 Cities Project and covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area (ZCTA) levels. It represents a first-of-its kind effort to release information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. The dataset includes estimates for 29 measures: 4 chronic disease-related risk behaviors, 13 health outcomes, 3 health status, and 9 on using preventive services. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2019 or 2018 data, Census Bureau 2010 population data, and American Community Survey (ACS) 2015–2019 or 2014–2018 estimates. The 2021 release uses 2019 BRFSS data for 22 measures and 2018 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours a night). Seven measures are based on the 2018 BRFSS because the relevant questions are only asked every other year in the BRFSS. More information about the methodology can be found at  www.cdc.gov/places.
The role of soil factors and leaf protein in the utilization of mopane plants by elephants in northern Botswana

Background
          Mopane (Colophospermum mopane) plants form monotypic woodlands that cover extensive areas in northern Botswana. Mopane is also a principal food item in the diet of elephants. Obtrusive damage to mopane plants as a result of elephant feeding may alter the structure of mopane woodlands. Some mopane woodland areas in northern Botswana are subjected to heavy elephant utilization rates whereas other mopane areas are less affected. However, the underlying reason for the concentrated elephant utilization is unknown.
        
        
          Results
          Ten mopane plots were subjected to sampling of soil properties that included structure, pH, nitrogen, phosphorus, potassium contents and protein contents. Elevated nitrogen and phosphorus contents in soils correlated with high protein levels in mopane leaves. Protein levels in leaves of mopane plants differed significantly between sites. However, multivariate analyses of environmental parameters and plots suggested that on a regional scale, there was no difference in the extent of elephant damage to mopane plants due to differential protein levels in leaves or any of the underlying soi factors that were examined.
        
        
          Conclusions
          From management perspective, this pattern mitigates the likelihood that an even more prolific elephant population will alter mopane woodland habitats irreversibly.
Provider Network Data: 2023 Quarter 2

This Provider Network Data contains information on individual and institutional providers participating in health plan networks from April through June 2023. Plan network data is collected from Medicaid, Commercial, and Exchange plans on a quarterly basis by the Department of Health, including managed care plans, as well as PPO/EPO plans.

For more information, please visit: <a href=https://pndslookup.health.ny.gov>https://pndslookup.health.ny.gov</a>
Compound 529961: 2,4-Dimethylthiolan-3-one

Chemical compound data from PubChem database. IUPAC Name: 2,4-dimethylthiolan-3-one. Molecular Formula: C6H10OS. Molecular Weight: 130.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2012 Uniform Reporting System (URS) Tables for Wyoming

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 527789: Benzoic acid, 3-chloro, 1-methyl-3-butenyl ester

Chemical compound data from PubChem database. IUPAC Name: pent-4-en-2-yl 3-chlorobenzoate. Molecular Formula: C12H13ClO2. Molecular Weight: 224.68. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Autoantibody profiling for the study and treatment of autoimmune disease

Proteomics technologies enable profiling of autoantibody responses using biological fluids derived from patients with autoimmune disease. They provide a powerful tool to characterize autoreactive B-cell responses in diseases including rheumatoid arthritis, multiple sclerosis, autoimmune diabetes, and systemic lupus erythematosus. Autoantibody profiling may serve purposes including classification of individual patients and subsets of patients based on their 'autoantibody fingerprint', examination of epitope spreading and antibody isotype usage, discovery and characterization of candidate autoantigens, and tailoring antigen-specific therapy. In the coming decades, proteomics technologies will broaden our understanding of the underlying mechanisms of and will further our ability to diagnose, prognosticate and treat autoimmune disease.
Compound 530045: 21-Hydroxyprogesterone, TMS derivative

Chemical compound data from PubChem database. IUPAC Name: 10,13-dimethyl-17-(2-trimethylsilyloxyacetyl)-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one. Molecular Formula: C24H38O3Si. Molecular Weight: 402.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2020 National Mental Health Services Survey (N-MHSS) State Profiles

These state profiles include data from facilities that reported to N-MHSS for the survey reference date April 30, 2020. The N-MHSS collects data on the location, characteristics, services offered, and number of clients (collected every other year) in treatment at mental health treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.
Compound 526971: meta-alpha-Hydroxymononitrodiphenylacetic acid, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2-hydroxy-2-(3-nitrophenyl)-2-phenylacetate. Molecular Formula: C15H13NO5. Molecular Weight: 287.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525427: 3,3-Dimethyl-2,4-dithiahexane

Chemical compound data from PubChem database. IUPAC Name: 2-ethylsulfanyl-2-methylsulfanylpropane. Molecular Formula: C6H14S2. Molecular Weight: 150.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
COVID-19 State Profile Report - New Hampshire

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Kentucky 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
2015 CMHS Uniform Reporting System (URS) Table for Oregon

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Oregon. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Behavioral Health Equity Report 2021

Behavioral Health Equity Report 2021: Substance Use and Mental Health Indicators Measured from the National Survey on Drug Use and Health (NSDUH), 2015–2019provides an update on a series of topics that focus on substance use and mental health (collectively referred to as behavioral health) in the United States. The Substance Abuse and Mental Health Services Administration (SAMHSA) selected specific topics and indicators in this report to represent a cross-section of the key behavioral health indicators that are assessed in SAMHSA data collections, including NSDUH. This report is intended to provide a concise, reader-friendly summary of key behavioral health measures for lay and professional audiences.
Compound 525441: 3,7-Dimethyl-4-thiaoctane

Chemical compound data from PubChem database. IUPAC Name: 1-butan-2-ylsulfanyl-3-methylbutane. Molecular Formula: C9H20S. Molecular Weight: 160.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401309-T1: [Translated] USE OF 2-FUORO-3-KETO ESTERS TO PRODUCE 3-FUORO-6,7,8,9-TETRAHYDRO-4H-PYRIMIDOÄ1,2-AUPYRIMIDINE-4-ONENES

Chemical patent from PubChem database. Patent Number: AT-E401309-T1. Title: Novel Drug Delivery System. Filing Date: 2000-08-03. Inventors: Patel, Amit, Jones, Michael. Abstract: The present invention discloses a drug delivery system designed to provide targeted and sustained release of therapeutic agents, improving patient com... IPC Classifications: C07D, C07F, A61K. This patent covers 31 claims related to 6 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 528869: Methyl 2,4-dimethyl-3-thienyl disulfide

Chemical compound data from PubChem database. IUPAC Name: 2,4-dimethyl-3-methylsulfanylthiophene. Molecular Formula: C7H10S2. Molecular Weight: 158.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530315: Hexadecanoic acid, 15-methyl-2-trimethylsilyloxy, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 15-methyl-2-trimethylsilyloxyhexadecanoate. Molecular Formula: C21H44O3Si. Molecular Weight: 372.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Emergency Temporary Shelters - Census

Under <a href="https://chicityclerkelms.chicago.gov/Matter/?matterId=6DEAA6D8-D0E6-EE11-904C-001DD806E058" target="_blank">SO2024-0008386</a>, passed by City Council on 4/17/2024, the Department of Family and Support Services publishes data on the City-operated and City-funded emergency new arrivals shelters. This dataset shows the total number of migrants who were in each shelter on each date listed.
Factors regulating Hb F synthesis in thalassemic diseases

Background
          The thalassemic syndromes originate from mutations of the globin genes that cause, besides the characteristic clinical picture, also an increased Hb F amount. It is not yet clear if there are more factors, besides the beta globin genotype, determining the Hb F production. We have tried to find out if there are relations between total Hb and Hb F, between erythropoietin (Epo) and Hb F, between Hb F and point mutations of the gamma gene promoters.
        
        
          Materials and Methods
          Hematologic parameters, iron status, alpha/non-alpha globin ratio, Epo level, and thalassemic defects of the alpha-, beta-, and gamma-globin genes were explored using standard methods in patients affected by thalassemic diseases. Ninety-five non thalassemic individuals have been examined as controls.
        
        
          Results
          Two clinical variants of beta-thalassemia intermedia referred to as beta-thal int sub-silent and evident are associated with distinct sets of mutations of the beta-globin gene. Silent beta thal mutations are invariably associated with sub-silent beta thal int; beta° or severe beta+ thal mutations are associated with evident beta thal int (88%) and almost invariably (98%) with thalassemia major. A positive correlation was observed between the severity of the disease and the Hb F level, but no correlation was found between the Hb F and erythropoietin (Epo) level. The mutation Ggamma -158 C→T was detected in 26.9% of patients affected by beta-thal int sub-silent and evident, respectively, but only in 2% of patients with thalassemia major.
        
        
          Conclusions
          The severity of beta-thal int and the increased Hb F level are strictly dependent from the type of beta-globin gene mutations. No relation is found between Hb F synthesis and Epo secretion. The mutation Ggamma -158 C→T, common among patients affected by beta-thal int and very rare in thal major patients, does not seem, in this study, to influence the Hb F content in beta thal int patients.
The functional genomic response of developing embryonic submandibular glands to NF-kappaB inhibition

Background
          The proper balance between epithelial cell proliferation, quiescence, and apoptosis during development is mediated by the specific temporal and spatial appearance of transcription factors, growth factors, cytokines, caspases, etc. Since our prior studies suggest the importance of transcription factor NF-κB during embryonic submandibular salivary gland (SMG) development, we attempted to delineate the emergent dynamics of a cognate signaling network by studying the molecular patterns and phenotypic outcomes of interrupted NF-κB signaling in embryonic SMG explants.
        
        
          Results
          SN50-mediated inhibition of NF-κB nuclear translocation in E15 SMG explants cultured for 2 days results in a highly significant increase in apoptosis and decrease in cell proliferation. Probabilistic Neural Network (PNN) analyses of transcriptomic and proteomic assays identify specific transcripts and proteins with altered expression that best discriminate control from SN50-treated SMGs. These include PCNA, GR, BMP1, BMP3b, Chk1, Caspase 6, E2F1, c-Raf, ERK1/2 and JNK-1, as well as several others of lesser importance. Increased expression of signaling pathway components is not necessarily probative of pathway activity; however, as confirmation we found a significant increase in activated (phosphorylated/cleaved) ERK 1/2, Caspase 3, and PARP in SN50-treated explants. This increased activity of proapoptotic (caspase3/PARP) and compensatory antiapoptotic (ERK1/2) pathways is consistent with the dramatic cell death seen in SN50-treated SMGs.
        
        
          Conclusions
          Our morphological and functional genomic analyses indicate that the primary and secondary effects of NF-κB-mediated transcription are critical to embryonic SMG developmental homeostasis. Relative to understanding complex genetic networks and organogenesis, our results illustrate the importance of evaluating the gene, protein, and activated protein expression of multiple components from multiple pathways within broad functional categories.
AFCARS 2020 New Technical Bulletins and Intro to NCWDMS

The Children's Bureau Data Analytics and Reporting Team held an AFCARS Open Office Hours for the implementation of AFCARS 2020 in December 2022. This session was for state and tribal program administrators, child welfare data leaders, and information system programmers. It was an opportunity to ask questions specific to an agency's implementation. Below is the slide deck of the question and answers that were presented during the session.

Metadata-only record linking to the original dataset. Open original dataset below.
Physician perceptions of primary prevention: qualitative base for the conceptual shaping of a practice intervention tool

Background
          A practice intervention must have its basis in an understanding of the physician and practice to secure its benefit and relevancy. We used a formative process to characterize primary care physician attitudes, needs, and practice obstacles regarding primary prevention. The characterization will provide the conceptual framework for the development of a practice tool to facilitate routine delivery of primary preventive care.
        
        
          Methods
          A focus group of primary care physician Opinion Leaders was audio-taped, transcribed, and qualitatively analyzed to identify emergent themes that described physicians' perceptions of prevention in daily practice.
        
        
          Results
          The conceptual worth of primary prevention, including behavioral counseling, was high, but its practice was significantly countered by the predominant clinical emphasis on and rewards for secondary care. In addition, lack of health behavior training, perceived low self-efficacy, and patient resistance to change were key deterrents to primary prevention delivery. Also, the preventive focus in primary care is not on cancer, but on predominant chronic nonmalignant conditions.
        
        
          Conclusions
          The success of the future practice tool will be largely dependent on its ability to "fit" primary prevention into the clinical culture of diagnoses and treatment sustained by physicians, patients, and payers. The tool's message output must be formatted to facilitate physician delivery of patient-tailored behavioral counseling in an accurate, confident, and efficacious manner. Also, the tool's health behavior messages should be behavior-specific, not disease-specific, to draw on shared risk behaviors of numerous diseases and increase the likelihood of perceived salience and utility of the tool in primary care.
NNDSS - Table II. Tetanus to Varicella

NNDSS - Table II. Tetanus to Varicella  - 2018. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states or territory.

Note:

This table contains provisional cases of selected national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up.  Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:

C.N.M.I.: Commonwealth of Northern Mariana Islands. 
U: Unavailable. —: No reported cases. N: Not reportable. NA:  Not Available.  NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

* Case counts for reporting years 2017 and 2018 are provisional and subject to change. Data for years 2013 through 2016 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf.
Compound 528851: 2,3,5,6-Tetrathiaheptane, 4-ethyl

Chemical compound data from PubChem database. IUPAC Name: 3-ethyl-1,2,4,5-tetrathiepane. Molecular Formula: C5H10S4. Molecular Weight: 198.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Meperidine hydrochloride

Demerol (meperidine hydrochloride) is a prescription opioid pain reliever used to manage moderate to severe pain. It comes in tablets (50mg, 100mg), injectables (25-100mg/ml), and syrup (50mg/5ml), but all forms are discontinued. As a Schedule II controlled substance, it carries risks of addiction and misuse. Consult a doctor for alternatives. This information was generated using AI and is provided for informational and research purposes only.
Compound 525702: p-Methoxybenzylidene-butyl-amine

Chemical compound data from PubChem database. IUPAC Name: N-butyl-1-(4-methoxyphenyl)methanimine. Molecular Formula: C12H17NO. Molecular Weight: 191.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.